Avoiding alcohol is removing a toxin, not adding a supplement. Heavier intake is costly; light intake is not a demonstrated longevity drug. Blood pressure, dream-stage sleep, and irregular-heartbeat burden move the expected way at zero. Heavy daily drinkers can seize or become delirious without medical support. People who do not enjoy drinking have no identified health dividend from starting. (Full Review)

Protocol

Target exposure

Zero ethanol

Including “just on weekends”; grams per week, not beverage type

How to stop

Stop at once or taper

Social and light drinkers usually stop at once; daily heavy drinkers taper under medical advice

Time of day

Continuous

Evening was the usual dosing window for sleep harm; late-day residual ethanol can still disrupt second-half-of-night sleep

Time to effect

Blood pressure

1–4 weeks

Larger fall when leaving heavier intake

Sleep architecture

First nights

REM (rapid-eye-movement) sleep can shift on the first ethanol-free nights

Cancer risk

Years-scale

Cumulative dose

Benefits

High: Lower blood pressure after reducing intake; less fragmented sleep architecture

Medium: Lower risk of several cancers; fewer atrial fibrillation recurrences in regular drinkers; better survival in alcohol-associated cirrhosis; fewer injuries and collision events

Low: Lower all-cause mortality, conflicted; lower coronary disease risk, conflicted; preservation of brain structure at low-to-moderate intakes; better training recovery and muscle protein synthesis; improved insulin sensitivity after short abstinence

Speculative: Longer telomeres; gut microbiome recolonization

Contraindications

Key Interactions

Acetaminophen (paracetamol): high-dose use after cessation still needs liver-aware limits

Benzodiazepines (diazepam, lorazepam), opioids (oxycodone, morphine), gabapentinoids (gabapentin, pregabalin), Z-drugs (non-benzodiazepine hypnotic sleep medications such as zolpidem): caution if used as an alcohol substitute

Warfarin and other narrow-therapeutic-index drugs: recheck INR (international normalized ratio) after intake goes to zero

Disulfiram, naltrexone, acamprosate, nalmefene: support abstinence; disulfiram makes any ethanol (including sauces and non-alcoholic beer residue) an absolute contraindication

GLP-1 receptor agonists (glucagon-like peptide-1 drugs; semaglutide, tirzepatide): potentiating; monitor overlapping gut events

Sedating supplements (high-dose kava, valerian, high-dose magnesium at night): caution as sleep substitutes in the first weeks; thiamine, magnesium, and zinc repletion often additive after heavy use

Non-alcoholic beer/wine: residual ethanol (often 0.05–0.5% ABV (alcohol by volume)); relevant for disulfiram, recovery programs, and PEth (phosphatidylethanol) testing

Risk & Side Effects

High: Alcohol withdrawal in physically dependent drinkers

Low: Transient rebound insomnia; fall in HDL cholesterol, conflicted

Speculative: Social friction and lost social ease; alcohol deprivation effect; loss of wine polyphenols; loss of an observational diabetes J-curve

Monitoring

Marker	Target	Why
PEth (phosphatidylethanol)	Below lab abstinence cutoff (often <20 ng/mL)	Objective recent ethanol
GGT	Often <20–30 U/L	Alcohol-sensitive liver enzyme
ALT	Often <19–25 U/L (women), <30 U/L (men)	Hepatocyte injury
AST	Similar to ALT; AST:ALT >2 suggests alcohol pattern	Pattern of injury
MCV	Roughly 80–90 fL	Macrocytosis from ethanol
Systolic / diastolic BP	<120 / <80 mm Hg	Ethanol raises blood pressure
hs-CRP	Often <0.5–1.0 mg/L	Residual inflammation
Ferritin	Individual; avoid unexplained elevation	Ethanol can raise iron load
HDL-C	No established target after cessation; track the person's own baseline	Known to drop after stopping

Cadence: Baseline before a planned stop; sleep and blood pressure in weeks 1–2; liver enzymes at about 4 weeks; then every 3–6 months in the first year if baseline was abnormal, otherwise every 6–12 months. PEth to confirm zero ethanol.

Qualitative Assessment

Sleep continuity and dream recall after week 2
Morning energy and resting heart rate / HRV (heart-rate variability) trend
Craving frequency and “automatic” pour cues
Training quality and next-day soreness
Social ease without a glass
Mood after the first two weeks, not only day 3

Avoiding Alcohol for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment